Last updated: February 15, 2026
Product Overview
NDC 60505-2675 corresponds to Derazantinib (ARinda), an investigational multikinase inhibitor targeting fibroblast growth factor receptor 2 (FGFR2) alterations. Currently, it has received regulatory clearance or approval only in certain jurisdictions for specific indications, primarily advanced cholangiocarcinoma, under an accelerated or conditional pathway.
Market Landscape
The global FGFR inhibitor market is expanding significantly, driven by the rising incidence of FGFR-altered cancers, including cholangiocarcinoma, urothelial carcinoma, and bladder cancer. The market dynamics are characterized by ongoing clinical trials, regulatory reviews, and potential approvals.
| Parameter |
Data Point |
| Global FGFR inhibitor market (2022) |
~$3 billion |
| Expected CAGR (2023-2030) |
12% |
| Major competitors |
Erdafitinib (JNJ), Pemigatinib (BMS), Infigratinib (QED) |
| Number of candidates in late-stage development |
5+ |
Potential Launch Scenario
- Assuming successful pivotal trial outcomes, regulatory approval for Derazantinib can be expected by 2024-2025 in the U.S. and Europe.
- The drug’s initial label might include cholangiocarcinoma with FGFR2 fusions or rearrangements.
- Commercial uptake will depend on the competitive positioning relative to existing FGFR inhibitors.
Pricing Context
Currently available FGFR inhibitors are priced as follows:
- Pemigatinib (Pemazyre): approximately $13,000/month in the U.S.
- Erdafitinib (Balversa): approximately $15,000/month in the U.S.
- Infigratinib: estimated at $12,000-$14,000/month in early commercialization stages in select markets.
Price Projections for NDC 60505-2675
- Given its likely positioning as a later entrant or an alternative to existing therapies, initial prices are projected between $12,000 and $15,000 per month, aligned with current market standards.
- If the drug demonstrates superior efficacy, safety profile, or convenience, price premiums of up to 10% could be justified.
- Prices could adjust downward if competitive pressures or biosimilar entrants emerge.
- The blockbuster threshold (>$1 billion annual revenue) would require the treatment to secure widespread use in the relevant indications, with annual treatment fees reaching approximately $150,000 per patient.
Market Penetration and Revenue Estimates
- Cholangiocarcinoma incidence globally: approximately 4-5 cases per 100,000 population; higher in Asia, Europe, U.S. (about 8,000-12,000 new cases annually in the U.S.).
- Penetration rate assumptions: 20-30% of eligible patients in the first five years post-launch.
- Revenue projection range (first five years):
- Year 1-2: ~$50-100 million, scaled strongly on approval speed, pricing, and payer coverage.
- Year 3-5: $250-500 million annually if market share stabilizes around 20-25%.
Regulatory and Commercial Challenges
- Competition from established drugs like Pemigatinib and Erdafitinib.
- Need for clear clinical differentiation and robust response data.
- Payer acceptance and pricing negotiations could influence market entry success.
Key Takeaways
- NDC 60505-2675 is poised for entry into a growing but competitive FGFR inhibitor market.
- Initial prices are expected in the $12,000–$15,000/month range, similar to existing products.
- Revenue potential hinges on approval timelines, clinical data, and market penetration.
- Market adoption will likely be constrained initially by competition but could expand significantly with positive clinical outcomes.
FAQs
-
What indications is NDC 60505-2675 expected to target?
It is primarily aimed at FGFR2-altered cholangiocarcinoma.
-
How does the pricing of NDC 60505-2675 compare to existing FGFR inhibitors?
It is likely to be priced similarly, around $12,000–$15,000 per month, matching current market standards.
-
When could the drug be commercially available?
Regulatory approval could occur between 2024 and 2025, depending on clinical trial results and review processes.
-
What factors influence its market success?
Clinical efficacy, safety profile, regulatory approval timing, competitive landscape, and payer acceptance.
-
How big is the potential patient market?
Estimated 8,000-12,000 new cases annually in the U.S. alone, with broader global prevalence in Asia and Europe.
References
[1] MarketWatch, “FGFR Inhibitors Market,” 2022.
[2] Global Data, “Oncology Agents Market,” 2023.
[3] FDA, “FDA Approval Database,” 2022.
[4] EvaluatePharma, “World Oncology Market,” 2022.
[5] IQVIA, “Market Dynamics for Oncology Drugs,” 2023.
